Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 176 participants.
Also called NCT06677970
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 176 participants
- Sponsor
- Registry
-
NCT06677970
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06677970. Randomized; single masking; primary purpose treatment. Start 2024-10-01 (actual); primary completion 2029-12-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- BP lowering drugs (nicardipine, labetalol, urapidil)
- Intervention (Drug)
- BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)
- Lead sponsor
- Yonsei University
Record details
- Record id
cardio:ct-nct06677970- Content hash
9cdd2923ddc21c2eed75ad4c455c7db038e790ea47715c52c0d8c57cc7a96fc4